Congenital Afibrinogenemia Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments
Congenital afibrinogenemia Pipeline Analysis report covers drugs of 4 companies currently in different phases of development. Congenital afibrinogenemia is an autosomal recessive blood coagulation disorder which is caused by mutations in one of the three genes; FGA, FGB, or FGG. Each of these genes is responsible for making a subunit of a protein (involved in blood clotting) known as fibrinogen. This condition does not allow blood to clot causing an impairment in the blood clotting process. A newborn suffering from this disease, after birth, experience prolonged bleeding from the umbilical cord stump. Symptoms of the disease include, nose bleeding, bleeding from the gums or tongue, bleeding into spaces between joints and muscles. Women suffering from congenital afibrinogenemia have abnormally heavy menstrual bleeding and experience spontaneous abortion. Other names for this condition include afibrinogenemia and familial afibrinogenemia.
The report provides Congenital afibrinogenemia treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are CSL and Octapharma among others.
- By Company
- By Phase
- By Molecule Type
- By Region
- By Route of Administration